Do you know of any suitable patients who might be eligible to take part in this clinical trial for myopic choroidal neovascularisation (mCNV)?

The POYANG trial aims to recruit approximately 280 participants across around 80 trial centres worldwide.

Key eligibility criteria for study participation:

• Age > 18 years ( >19 years in Korea)
• Treatment-naïve CNV resulting from pathological myopia
• Diagnosis of active myopic CNV in one eye
• BCVA of 78 to 24 letters inclusive (approximately 20/32 to 20/320 Snellen equivalent)
• Sufficiently clear ocular media and adequate pupillary dilation to enable the acquisition of high-quality retinal images to confirm the diagnosis
• No myopic tractional maculopathy/schisis
• No epiretinal membrane
• No uveitis

Study protocol:

The Poyang study will last approximately 52 weeks and will comprise the following:

• A screening period during the first 28 days
• A 48-week study period during which the study treatment will be administered on a PRN schedule following an initial active IVT treatment at randomisation (Day 1) (faricimab 6 mg or ranibizumab 0.5 mg).
• The final study visit will take place in week 48; no study treatment will be administered at this visit.
• During this period, approximately 15 patient visits to our study centre are planned.

Further information on faricimab and the study is available here.